Amoxapine
Asendin (amoxapine) is a small molecule pharmaceutical. Amoxapine was first approved as Asendin on 1982-01-01. It is used to treat depressive disorder, psychophysiologic disorders, and psychotic affective disorders in the USA. The pharmaceutical is active against sodium-dependent noradrenaline transporter and sodium-dependent serotonin transporter. In addition, it is known to target 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 7, and 5-hydroxytryptamine receptor 2A.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amoxapine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ASENDIN | Lederle Laboratories | N-018021 DISCN | 1982-01-01 | 4 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amoxapine | ANDA | 2015-02-28 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
28 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute kidney injury | D058186 | HP_0001919 | N17 | 1 | — | 1 | 1 | 1 | 4 |
| Anesthesia | D000758 | — | 1 | — | 2 | — | 3 | ||
| Post-dural puncture headache | D051299 | — | — | 1 | 1 | — | 2 | ||
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | 1 | — | 1 |
| Chronic renal insufficiency | D051436 | N18 | — | — | — | 1 | — | 1 | |
| Heart block | D006327 | I45.89 | — | — | — | 1 | — | 1 | |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | 2 | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart arrest | D006323 | EFO_0009492 | I46 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Altitude sickness | D000532 | EFO_1000782 | T70.29 | 2 | — | — | — | — | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
| Premature obstetric labor | D007752 | O60 | 1 | — | — | — | — | 1 | |
| Urinary bladder neoplasms | D001749 | C67 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | AMOXAPINE |
| INN | amoxapine |
| Description | Amoxapine is a dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position. It has a role as an antidepressant, an adrenergic uptake inhibitor, a dopaminergic antagonist, a serotonin uptake inhibitor and a geroprotector. |
| Classification | Small molecule |
| Drug class | tricyclic compounds |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2 |
Identifiers
| PDB | — |
| CAS-ID | 14028-44-5 |
| RxCUI | 722 |
| ChEMBL ID | CHEMBL1113 |
| ChEBI ID | 2675 |
| PubChem CID | 2170 |
| DrugBank | DB00543 |
| UNII ID | R63VQ857OT (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A2
SLC6A2
SLC6A4
SLC6A4
Organism
Homo sapiens
Gene name
SLC6A2
Gene synonyms
NAT1, NET1, SLC6A5
NCBI Gene ID
Protein name
sodium-dependent noradrenaline transporter
Protein synonyms
NET, neurotransmitter transporter, Norepinephrine transporter, solute carrier family 6 (neurotransmitter transporter), member 2, solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2, Solute carrier family 6 member 2, solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a2 (20538)
sodium-dependent noradrenaline transporter (Q6QU62)
Alternate
HTR6
HTR6
HTR2C
HTR2C
HTR7
HTR7
HTR2A
HTR2A
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 951 documents
View more details
Safety
Black-box Warning
Black-box warning for: Amoxapine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
690 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more